(Q41702059)

7 October 2017

1 reference

title

Individualization of cancer therapy based on cytochrome P450 polymorphism: a pharmacogenetic approach (English)

1 reference

7 October 2017

0 references

Vermes A

1

1 reference

7 October 2017

Guchelaar HJ

series ordinal

2

1 reference

7 October 2017

Koopmans RP

series ordinal

3

1 reference

7 October 2017

publication date

1 September 1997

1 reference

7 October 2017

published in

Cancer Treatment Reviews

1 reference

7 October 2017

volume

23

1 reference

7 October 2017

issue

5-6

1 reference

7 October 2017

page(s)

321-339

1 reference

Genetic differences in drug disposition

7 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Genetically determined differences in drug metabolism as a risk factor in drug toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Molecular mechanisms of genetic polymorphisms of drug metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Role of genetics and drug metabolism in human cancer risk

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Methylation pharmacogenetics: thiopurine methyltransferase as a model system

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Newer antidepressants and the cytochrome P450 system

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

P450 genes: structure, evolution, and regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

High-resolution crystal structure of cytochrome P450cam

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Nomenclature for human CYP2D6 alleles

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Evolution of the cytochrome P450 genes

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Evolution of the P450 gene superfamily: animal-plant 'warfare', molecular drive and human genetic differences in drug oxidation

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Characterization of the common genetic defect in humans deficient in debrisoquine metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Lung cancer and the debrisoquine metabolic phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Metabolism of oxazaphosphorines

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Ifosfamide--pharmacology, safety and therapeutic potential

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Activation of the anti-cancer drug ifosphamide by rat liver microsomal P450 enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Does acrolein contribute to the cytotoxicity of cyclophosphamide?

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Dechloroethylation of ifosfamide and neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Characterization of the cytochrome P450 involved in side-chain oxidation of cyclophosphamide in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

The clinical pharmacology of etoposide and teniposide

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

In vitro metabolism of etoposide (VP-16-213) by liver microsomes and irreversible binding of reactive intermediates to microsomal proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26)

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Mechanism of action of taxol

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: a review.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Isolation, structural determination, and biological activity of 6 alpha-hydroxytaxol, the principal human metabolite of taxol

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Clinical pharmacokinetics of paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Chemoprevention of breast cancer by tamoxifen: risks and opportunities

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

A risk-benefit assessment of tamoxifen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

New Perspective on Cancer of the Contralateral Breast: A Marker for Assessing Tamoxifen as a Preventive Agent

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Species differences in the covalent binding of [14C]tamoxifen to liver microsomes and the forms of cytochrome P450 involved

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Single and repeated dose pharmacokinetics of thio-TEPA in patients treated for ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

One-day VATH (vinblastine, Adriamycin, thiotepa, and Halotestin) therapy for advanced breast cancer refractory to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Thiotepa bladder instillations: therapy and prophylaxis for superficial bladder tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Metabolism and alkylating activity of thio-TEPA in rat liver slice incubation

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. II. Vinblastine and vincristine

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Comparative pharmacokinetics of vindesine, vincristine and vinblastine in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Interpatient and intrapatient variability in vinblastine pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Effects of 5-fluorouracil treatment on rat liver microsomal enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

Action of methotrexate on cytochrome P-450 monooxygenases in rats. Study performed with [13C]-aminopyrine micro breath test

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

The clinical pharmacology of 6-mercaptopurine

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990031-1

7 January 2021

10.1016/S0305-7372(97)90031-1

Identifiers

DOI

1 reference

7 October 2017

1 reference